A candidate vaccine against human papillomavirus serotypes 16 and 18 appears to induce robust immune responses to antigens, potentially leading to the elimination of virus-infected cells and regression of dysplasia, say US investigators.
via Med Wire News
via Med Wire News
No comments:
Post a Comment